@AcademyHealth #ARM2018 attendees: join me on Monday at 3:15 pm in room 605-606, where Anirban Basu will present our work in collaboration with the Patient Centered Outcomes Research Institute (PCORI) to quantify the potential economic impact of the findings from comparative-effectiveness research studies.
Our goal was to understand the potential benefits of implementing comparative-effectiveness research findings. We developed a common modeling framework across multiple disease conditions and interventions to estimate the impact for different stakeholders. This will not be a conversation about value… but enumerating costs and consequences.
Common Modeling Framework
We developed four economic models to evaluate the potential impact of four studies selected by PCORI:
- Antibiotics administered intravenously via a peripherally inserted central venous catheter (PICC) or orally for post-discharge treatment of children with acute osteomyelitis or complicated pneumonia using
- Warfarin versus to anticoagulation among anticoagulation naïve elderly acute ischemic stroke patients, who are discharged alive with documented persistent or paroxysmal atrial fibrillation/flutter
- Use of self-monitor blood glucose (SMBG) for non-insulin-treated patients with type 2 diabetes
- Shared decision-making using a decision aid with usual care in the choice of admission for observation and further cardiac testing or for referral for outpatient evaluation in patients with possible acute coronary syndrome
- Session: “Implementing PCOR Results to Inform Choices and Improve Healthcare Delivery”
- Time: Monday, June 25, 2018 3:15 PM – 4:45 PM
- Location: Room 605-606, Washington State Convention Center, Seattle, WA
Stay tuned for more details that will become available soon in a full-length manuscript.
These are results from joint work I conducted with Anirban Basu, in collaboration with PCORI research staff, Joanna Siegel and William Lawrence. The work carried out under Salutis Consulting LLC and funded by PCORI.